Notice on Convocation of Annual General Meeting of Shareholders of AB Klaipėdos nafta
Notice is hereby given that on the initiative and by the resolution of the Board of AB Klaipėdos nafta, legal entity code 110648893, with the registered office at Burių str. 19, Klaipeda (hereinafter - the Company), Annual General Meeting of Shareholders of the Company will be held on 22 April 2022 at 10:00 a.m. The meeting will be held in the Company’s office at Buriu str. 19, Klaipeda, in the administrative office of the Company (in the hall of the meeting on the 2nd floor).
Agenda of the meeting:
- Announcement of the Auditor’s Report regarding the Financial Statements and Annual Report of the Company for the year 2021 to the shareholders;
- Announcement of the Annual Report of the Company for the year 2021 to the shareholders;
- Approval of the audited Financial Statements of the Company for the year 2021;
- Approval of the appropriation of profit (loss) of the Company for the year 2021;
- Approval of Report on the remuneration of the Company;
It is recommended that all shareholders participate in the meeting by completing the general ballot paper and submitting it in advance to the Company. Please inform us about the need to physically attend the General Meeting of Shareholders no later than 3 business days before General Meeting of Shareholders via below specified emails. In all cases, Shareholders of the Company without personal protective equipment will not be allowed to participate in to the General Meeting of Shareholders. The Company reserves the right not to allow participation in to the General Meeting of Shareholders for those shareholders whose health condition are reasonably doubtful.
The shareholders will be registered from 09:00 a.m. to 09:55 a.m. The persons intending to participate in the meeting shall have a personal ID document (an authorized representative shall have an authorization approved under the established procedure. The natural person’s authorization shall be notarized. An authorization issued in a foreign state shall be translated into the Lithuanian language and legalized under the procedure prescribed by the laws).
A shareholder or his proxy shall have the right to vote in writing in advance by filling in a general ballot paper. At the request of the shareholder, the Company shall send a general ballot paper to the shareholder by registered mail free of charge at least 10 days before the meeting. The filled-in general ballot paper and the document attesting the voting right shall be submitted to the Company no later than until the meeting, sending by registered mail or providing them at the address of the registered office of the Company indicated in the notice.
The shareholders who hold shares carrying at least 1/20 of all the votes may propose additions to the agenda of the general meeting of shareholders by submitting with every proposed additional item of the agenda a draft resolution of the general meeting of shareholders or, when no resolution is required, an explanation. Proposals on addition to the agenda shall be submitted in writing or sent by e-mail. Written proposals shall be submitted to the Company on business days or sent by registered mail at the address of the registered office of the Company indicated in the notice. Proposals submitted by e-mail shall be sent to the following e-mails: email@example.com and firstname.lastname@example.org. The agenda shall be supplemented if the proposal is received no later than 14 days before the Ordinary General Meeting of Shareholders. If the agenda of the general meeting of shareholders is supplemented, the Company shall notify on the additions no later than 10 days before the meeting in the same ways as in the case of convocation of the meeting.
The shareholders, who hold shares carrying at least 1/20 of all the votes, at any time before the general meeting of shareholders or during the meeting, may propose new draft resolutions on items which are or will be included in the agenda of the meeting. The proposals may be submitted in writing or sent by e-mail. Written proposals shall be submitted to the Company on business days or sent by registered mail at the address of the registered office of the Company indicated in the notice. Proposals submitted by e-mail shall be sent to the following e-mails: email@example.com and firstname.lastname@example.org.
The shareholders shall have the right to submit to the Company in advance questions relating to the items on the agenda of the meeting. The shareholders may submit their written questions to the Company on business days or send by registered mail at the address of the registered office of the Company indicated in the notice no later than 3 business days before the meeting. The Company will reply to the questions by e-mail or in writing before the meeting, except the questions which are related to the Company’s commercial (industrial) secret, confidential information or which have been submitted later than 3 business days before the meeting.
The Company does not provide the possibility of participating and voting at the meeting by means of electronic communications.
The shareholder shall have the right to authorize through electronic communications means another person (natural or legal) to participate and vote in the meeting on behalf of the shareholder. No notarization of such authorization is required. The shareholder must confirm the proxy issued through electronic communications means by an electronic signature developed by a secure signature-creation device and approved by a qualified certificate effective in the Republic of Lithuania. The shareholder shall inform the Company on the proxy issued through electronic communications means to the following e-mails: email@example.com and firstname.lastname@example.org no later than until the last business day before the meeting at 10:00 a.m. The proxy and the notice must be issued in writing. The proxy and the notice to the Company shall be signed with the electronic signature but not the letter sent by e-mail. By submitting the notice to the Company, the shareholder shall include the internet address from which it would be possible to download software free of charge to verify the shareholder’s electronic signature.
The record date of the meeting shall be 14 April 2022 (only those persons who will be shareholders of the Company at the close of the record date of the general meeting of shareholders or their authorized persons, or persons with whom an agreement on assignment of the voting right has been executed, may participate and vote at the general meeting of shareholders).
The record date which entitles shareholders to receive a portion of the Company’s profit (dividend) – 6 May 2022.
The shareholders of the Company may familiarise with the draft resolution of the meeting and the form of the general ballot paper under the procedure prescribed by the laws in the registered office of the Company at Buriu str. 19, Klaipeda (tel.: 8 46 391636), or on the Company’s website at http://www.kn.lt/. The following information and documents shall be provided on the abovementioned internet website of the Company:
- The notification on convocation of the meeting;
- Total number of the Company’s shares and the number of shares with voting rights on the convening day of the meeting.
Mindaugas Kvekšas, Chief Financial Officer, +370 614 82665.
Orinta Barkauskaitė, Head of Communication +370 611 27985
- Annex No 1_Draft decisions_GMS_EN_2022-04-22
- Annex No. 2_Ballot paper_GMS_EN_2022-04-22
- Annex No. 3_Financial statements for the year of 2021
- Annex No. 3_Financial statements for the year 2021_XHTML
- Annex No. 4_Appropriation of profit (loss) of AB Klaipedos nafta
- Annex No. 5_2021 AB Klaipėdos nafta Report on Remuneration
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Joint Press Release – Kalera and Agrico Announce Effectiveness of Registration Statement, Waiver of Minimum Cash Condition and Extraordinary General Meetings for Proposed Business Combination16.5.2022 08:00:00 CEST | Press release
Extraordinary general meeting of Kalera shareholders (the “Kalera Special Meeting”) and extraordinary general meeting of Agrico shareholders (the “Agrico Special Meeting” and, together with the Kalera Special Meeting, the “Special Meetings”) to approve the proposed business combination of Kalera and Agrico expected to be held on June 27, 2022. Record date for the Kalera Special Meeting is June 6, 2022 (the “Kalera Record Date”); Record date for the Agrico Special Meeting is May 12, 2022 (the “Agrico Record Date” and, together with the Kalera Record Date, the “Record Dates”).Kalera shareholders as of June 6, 2022 voting by proxy should submit their vote by June 22, 2022.Agrico shareholders as of May 12, 2022 voting by proxy should submit their vote by 10:00 a.m., Eastern Time on June 25, 2022.Kalera has waived the minimum cash closing condition. Despite the waiver of the condition, if the minimum cash condition is not satisfied upon the consummation of the business combination, Agrico’s
Inventiva secures a €50 million credit facility from the European Investment Bank16.5.2022 08:00:00 CEST | Press release
This credit facility is intended to support the progress and expansion of Inventiva’s pipelineThe credit facility consists of two tranches of €25 million eachCredit agreement is part of the European Investment Bank’s strategy to support biotech companies developing a high-level of expertise in various therapeutic areas with significant unmet medical needs Daix (France), Long Island City (New York, United States), May 16, 2022 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with non-alcoholic steatohepatitis (NASH) and other diseases with significant unmet medical needs, today announced the signing of a €50 million bullet credit facility agreement with the European Investment Bank (“EIB”). The Company plans to use the facility toward its preclinical and clinical pipeline, including to help fund a portion of its Phase III clinical trial of lan
Immunicum AB: Immunicum tillkännager positiva interimsresultat från ADVANCE II-studie i AML-underhållsbehandling16.5.2022 08:00:00 CEST | Pressemelding
Analys av primärstudiens effektmått slutfördes med 7 patienter som visade ett mätbar restsjukdom (MRD)-svar, varav 5 patienter konverterade från MRD+ till MRD- och 2 patienter som visade en avsevärd, minst 10-faldig, minskning av MRD efter behandling med DCP-001Efter en medianuppföljningsperiod på 14,3 månader har medianen för återfallsfri överlevnad (RFS) och total överlevnad (OS) ännu inte uppnåtts.Estimerad RFS vid 6 månader baserad på för närvarande tillgänglig data är 83,7% och estimerad 6-månaders OS är 97,0%Immunicum planerar att presentera fler uppdateringar av överlevnadsdata, inklusive RFS och OS, samt immunövervakningsdata under Q4 2022Företaget håller konferenssamtal och webbsändning i dag kl. 14:00 CET (8:00am ET, 1.00pm GMT) Immunicum AB (“Immunicum” publ; IMMU.ST), ett bioläkemedelsföretag fokuserat på behandlingar mot tumörrecidiv och svårbehandlade etablerade tumörer, tillkännagav idag uppdaterade interimsresultat från det pågående ADVANCE II kliniska test som utvärder
Immunicum AB: Immunicum Announces Positive Interim Results from ADVANCE II Study in AML Maintenance Treatment16.5.2022 08:00:00 CEST | Press release
Analysis of primary study endpoint was completed with 7 patients showing a measurable residual disease (MRD) response, of which 5 patients converted from MRD+ to MRD- and 2 patients showed a substantial, at least 10-fold reduction in MRD following treatment with DCP-001After a median follow-up period of 14.3 months, median relapse-free survival (RFS) and overall survival (OS) have not yet been reachedThe estimated 6-month RFS based on the currently available data is 83.7% and the estimated 6-month OS is 97.0%Immunicum plans to present further updates on survival data including RFS and OS, as well as immunomonitoring data in Q4 2022Company to host conference call and webcast today at 14:00 CET (8am ET, 1pm GMT) Immunicum AB (“Immunicum” publ; IMMU.ST), a biopharmaceutical company focused on therapies addressing tumor recurrence and hard-to-treat established tumors, announced today updated interim results from the ongoing ADVANCE II clinical trial evaluating the company’s lead developmen
Energy partnership agreement between Vantaa Energy and SATO supports the achievement of SATO’s carbon neutrality target16.5.2022 08:00:00 CEST | Press release
SATO Corporation Press release 16 May 2022 at 9:00 am In February 2022, Vantaa Energy and SATO signed an energy partnership agreement that aims to support the achievement of SATO’s carbon neutrality target by 2030. Vantaa Energy leads the way in climate-friendly energy production and enables smooth everyday life for its customers by constantly developing climate-friendly energy services throughout the property lifecycle. SATO is one of Finland’s largest rental housing providers and makes carefree and sustainable rental housing available for its customers. The purpose of the cooperation between Vantaa Energy and SATO is to together promote and develop carbon-neutral energy solutions for the heating and cooling of buildings as well as new innovative ways to reduce energy consumption so that SATO will reach its targets in line with its strategy. Improving the energy efficiency of properties cuts heating costs and is one of the most important actions taken by SATO to curb climate change an